Danish biopharmaceutical company Genmab has finalized the $8 billion acquisition of Netherlands-based Merus NV, strategically expanding its cancer treatment portfolio with Merus’ late-stage bispecific antibody, petosemtamab. This addition, which has shown promising Phase II results when combined with Merck's Keytruda in head and neck cancer, positions Genmab for a shift from a royalty-focused model to full drug development and commercialization. The acquired candidate holds potential blockbuster status with multiple Breakthrough Therapy Designations from the FDA, underpinning Genmab's confidence in transforming cancer care and sustaining long-term growth through a diversified pipeline.